professionalIMG

William T. Whelan

Member vCard
Boston
617.348.1869



Education

  • Boston University (JD)
  • Middlebury College (BA)

Bar Admissions

  • Massachusetts

Languages

  • French

Bill serves as Co-chair of the firm’s Life Sciences Practice. He focuses his practice on securities law, venture capital, and mergers and acquisitions. He regularly represents technology-based companies, principally in the areas of biotechnology, medical technologies, energy and clean technology, and software. He routinely counsels these clients on many aspects of their corporate development, from initial organization and acquisition of technology, through private financing and initial public offering, to strategic alliances and business combination transactions. He also regularly represents venture capital firms in portfolio investment activities and underwriters in public offerings and private placements of equity securities.

Bill has lectured at various Massachusetts Continuing Legal Education seminars on topics relating to corporate organization and mergers and acquisitions.

During law school, he served as editor-in-chief of the Boston University Law Review. Bill is a former law clerk to the Chief Judge of the US Court of Appeals for the District of Columbia Circuit.

Representative Matters


Mergers & Acquisitions

  • Represented Ember Corporation in its merger with Silicon Laboratories, Inc. (NASDAQ: SLAB)
  • Represented Pluromed, Inc. in its merger with Sanofi
  • Represented Boston Biomedical, Inc. in its merger with Dainippon Sumitomo Pharma Co., Ltd.
  • Represented Caliper Life Sciences, Inc. (Nasdaq: CALP) in its merger with PerkinElmer, Inc. (NYSE: PKI)
  • Represented Visigen Biotechnologies, Inc. in its merger with Invitrogen Corporation (currently known as Life Technologies, Inc. (Nasdaq: LIFE))
  • Represented V.I. Technologies, Inc. (Nasdaq: VITX) in its merger with Panacos Pharmaceuticals, Inc. (Nasdaq: PANC)
  • Represented EPIX Pharmaceuticals, Inc. (Nasdaq: EPIX) in its merger with Predix Pharmaceuticals, Inc.
  • Represented Caliper Life Sciences, Inc. (Nasdaq: CALP) in its merger with Xenogen Corporation (Nasdaq: XGEN)
  • Represented Focus Technologies Holding Company in its acquisition by Quest Diagnostics Incorporated (NYSE: DGX)
  • Represented the MacGregror Group, Inc. in its acquisition by Investment Technology Group, Inc. (NYSE: ITG)

Public & Private Offerings for Public Companies

  • Represented Intercept Pharmaceuticals, Inc. (Nasadq:  ICPT) in its initial public offering
  • Represented BG Medicine, Inc. (Nasdaq: BGMD) in its initial public offering
  • Represented Coley Pharmaceutical Group, Inc. (Nasdaq: COLY) in its initial public offering
  • Represented Panacos Pharmaceuticals, Inc. (Nasdaq: PANC) in a follow-on public offering
  • Represented EPIX Pharmaceuticals, Inc. (Nasdaq: EPIX) in its initial public offering and a Rule 144A offering of convertible notes
  • Represented Predix Pharmaceuticals, Inc. in its initial public offering

Venture Capital Financings

  • Represented Anchor Therapeutics, Inc. in various preferred stock and debt financings
  • Represented BG Medicine, Inc. in various preferred stock and debt financings
  • Represented Aureon Laboratories, Inc. in various preferred stock and debt financings
  • Represented Pulmatrix, Inc. in various preferred stock and debt financings
  • Represented Luminus Devices, Inc. in various preferred stock and debt financings

Recognitions & Awards

  • Chambers USA: Massachusetts – Corporate/Mergers & Acquisitions (2014)
  • Recommended by The Legal 500 United States for Healthcare: Life Sciences (2013)
  • Best Lawyers in America: Biotechnology Law (2013 – 2014)
  • Martindale-Hubbell AV Preeminent   

Professional & Community Involvement

  • Past member, MIT Innovations Committee
  • Member, American Bar Association
  • Member, Massachusetts Bar Association
  • Member, Boston Bar Association

Create PDF

Include:

  • Publications
    • Alerts & Advisories
    • Industry Reports & Newsletters
    • Published Articles
  • Speaking Engagements
  • Newsroom
    • Press Releases
    • In The News